The Complete Guide to How Long Drug Patents Last Across the Commonwealth of Independent States (CIS)
Why CIS Patent Terms Confuse Even Experienced IP Professionals When a pharmaceutical company’s legal team maps out its global IP […]
How Biopharma Business Development Teams Are Building 5-Year LOE Dashboards to Protect Revenue, Time Deals, and Outmaneuver the Competition
Every year, pharmaceutical executives sit in board rooms and learn that a product generating hundreds of millions of dollars in
Turn Your Drug’s Patent Clock Into a Revenue Multiplier: Lifecycle Management and the 505(b)(2) Pathway
The Hatch-Waxman Act was never designed to be a gift to branded pharmaceutical companies. Congress passed the Drug Price Competition
Buy Old Science Cheap, Sell Proven Biology Expensive
This is the arbitrage opportunity. The pharmaceutical secondary market — distressed assets, out-licensed compounds, abandoned pipelines, post-patent small molecules —
Buy Old Science Cheap, Sell Proven Biology Expensive Read Post »
Sell the Bridge, Not the Gap: How to Turn Expiring Patents into Multi-Billion Dollar Reformulations
The instinct, when a primary patent approaches expiration, is to treat it as a loss event. Revenue projections get marked
Turn Abandoned Patents Into Profit
The pharmaceutical industry operates on a high-risk model where the cost of a single drug approval ranges from $1 billion
Turn Abandoned Patents Into Profit Read Post »
Drug Reformulation Strategy: Buy Seven Years of Exclusivity for $20 Million
Pharmaceutical manufacturers face a revenue contraction of 62% from their top-selling assets by 2030.1 Blockbuster drugs representing $236 billion in
Drug Reformulation Strategy: Buy Seven Years of Exclusivity for $20 Million Read Post »
Sell Before the Cliff Drops: A BD Playbook for Biopharma Equipment Suppliers
How to use market automation and drug patent intelligence to build pipeline before generic entry kills your best customers’ budgets
Sell Before the Cliff Drops: A BD Playbook for Biopharma Equipment Suppliers Read Post »
Forecasting Generic Entry: Combining FDA Orange Book with Paragraph IV Notice Letters
Pharmaceutical companies lose between $200 billion and $400 billion in annual revenue to patent expirations between 2025 and 2030. This
Forecasting Generic Entry: Combining FDA Orange Book with Paragraph IV Notice Letters Read Post »
